Download PDFPDF
Concise report
Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    SF-36 improves in a 6-week RA trial: so what?

    Dear Editor,

    Dear editor,

    I was disappointed in the publication of the concise report on the effects of an orally active Janus kinase (JAK) inhibitor on patient-reported outcomes in rheumatoid arthritis (RA). [1] JAK inhibition represents a new treatment option with potential in RA, so the results of the proof-of-concept trial were of interest, even though it lasted only 6 weeks; and these were duly published.[...

    Show More
    Conflict of Interest:
    None declared.